Literature DB >> 6086247

Efficacy of cefotaxime and latamoxef for Escherichia coli bacteremia and meningitis in newborn rats.

K S Kim, M Manocchio, A S Bayer.   

Abstract

We have evaluated the efficacy of cefotaxime and latamoxef against a Kl Escherichia coli strain in vitro and in vivo. In vitro, the minimal inhibitory concentrations (MICs) were close to the minimal bactericidal concentrations (MBCs) for both antibiotics (less than or equal to 2 dilutions). However, with an inoculum of 10(7) CFU/ml, MIC and MBC were significantly greater than those with inocula of 10(3) and 10(5). In vivo study with an infant rat model of bacteremia and meningitis revealed that both cefotaxime and latamoxef penetrated well into the cerebrospinal fluid (CSF), both drugs were bactericidal in blood and CSF, both were effective in prevention of the development of meningitis in bacteremic animals, and the mortality rates were significantly less in the treated than in the control group (p less than 0.001). However, even with cefotaxime or latamoxef treatment, the mortality was significantly greater (p less than 0.001) in rats whose bacterial counts before therapy were greater than or equal to 10(6) CFU/ml of blood. These findings suggest that the effects of cefotaxime and latamoxef may be directly correlated with the size of the bacterial population exposed to these agents and that this variable may be an important factor to influence the therapeutic outcome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086247     DOI: 10.1159/000238278

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  10 in total

Review 1.  Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid.

Authors:  I Lutsar; I R Friedland
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

2.  Efficacy of gatifloxacin in experimental Escherichia coli meningitis.

Authors:  I Lutsar; I R Friedland; H S Jafri; L Wubbel; W Ng; F Ghaffar; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 3.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 4.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

5.  Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15.

Authors:  Flavie Pouillot; Maryline Chomton; Hélène Blois; Celine Courroux; Julien Noelig; Philippe Bidet; Edouard Bingen; Stéphane Bonacorsi
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

6.  Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci.

Authors:  K S Kim; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

7.  Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats.

Authors:  Y H Tsai; M Bies; F Leitner; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

8.  Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.

Authors:  A S Bayer; D Norman; K S Kim
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

9.  Efficacy of cefmenoxime in experimental Escherichia coli bacteremia and meningitis.

Authors:  K S Kim
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

10.  The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat.

Authors:  K S Kim; H Itabashi; P Gemski; J Sadoff; R L Warren; A S Cross
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.